Exjade

Selected form

Deferasirox

Method of action: All Other Therapeutic Products, Complexing, Heavy Metal Chelator

Treatment option: Iron Overload, Blood Transfusion

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exjade

Quick Facts

Property	Description
Active ingredient	Deferasirox
Form	Oral dispersible tablets and film-coated tablets
Pharmacological class	Iron-chelating agent
Common use	Management of chronic iron overload (Hemosiderosis)
Origin	Synthetic, non-peptide triazole derivative

What Type of Medicine is Exjade (Deferasirox)?

Exjade is a pharmaceutical preparation whose active ingredient is Deferasirox, a synthetic compound clinically recognized as a highly selective iron-chelating agent. This medicine belongs to a class of drugs that specifically targets the removal of excessive iron from the body. Deferasirox is a single-ingredient product derived from a triazole chemical structure, a key differentiating feature that allows for its effectiveness via the oral route of administration. The drug's design provides a non-invasive alternative to older chelation methods that historically required prolonged infusion. The oral dosage forms available are distinct: the original dispersible tablets and the later film-coated tablets (sometimes marketed as Jadenu), offering flexibility in a patient's daily management routine.

What is the General Purpose of an Iron Chelator?

The fundamental general purpose of Exjade is to support the body in binding to and removing accumulated excess iron, a condition clinically referred to as chronic iron overload or hemosiderosis. For patients who require frequent blood transfusions, iron can build up over time. Deferasirox achieves its general purpose through chelation, where it forms a stable complex with the harmful ferric iron (Fe^3+) within the blood and tissues. Clinical data indicates the efficacy of Deferasirox in promoting the excretion of this iron from the body via bile and feces. This action is crucial for mitigating the potential damage caused by unchecked iron deposition in vital organs, supporting long-term health maintenance.

Regulatory References

Deferasirox: MedlinePlus Drug Information

What side effects are possible with Exjade?

Possible Side Effects and Safety Information

The safety profile of Deferasirox (Exjade) is officially categorized by regulatory bodies based on the frequency and system-organ class of documented adverse reactions. The medicine is associated with risks to the renal, hepatic, and gastrointestinal systems.

Frequency Classification

Side effects are classified according to incidence observed in clinical use:

Frequency Classification	Common Adverse Reactions (Examples)
Very Common (ge 1/10)	Increased blood creatinine
Common (ge 1/100 to < 1/10)	Diarrhea, Nausea, Vomiting, Abdominal pain, Skin rash, Increased transaminases

Some common effects, such as skin rashes and increases in blood creatinine, are often observed at the beginning of treatment and may become less frequent over time.

Serious Adverse Reactions

Official labeling documents significant risks, which include the potential for acute kidney injury (including acute renal failure), hepatic failure, and gastrointestinal hemorrhage or perforation. Other serious documented reactions include severe skin reactions (such as Stevens-Johnson syndrome, SJS) and bone marrow suppression.

Population-Specific Safety Notes

Official prescribing information notes that older adults (geriatric population) are at an increased risk of adverse events, including a higher risk of severe gastrointestinal bleeding. Furthermore, the use of Deferasirox is contraindicated in patients with severe renal impairment (creatinine clearance less than 40 mL/ min) or severe hepatic impairment (Child-Pugh C), reflecting formal regulatory safety restrictions.

Overdose and Emergency Response

An overdose of Deferasirox (Exjade) is characterized by an acute exaggeration of the drug's known toxicities, with the official regulatory profile focused on severe, life-threatening systemic risks. Documented manifestations of overdose include acute gastrointestinal symptoms such as diarrhoea, vomiting, nausea, and abdominal pain. A key laboratory sign is an acute increase in serum creatinine, indicative of renal stress.

The most serious outcomes documented in regulatory labeling are acute renal failure, hepatic failure, and severe gastrointestinal hemorrhage, all of which have been reported with fatal outcomes. Additionally, metabolic acidosis has been cited as a severe complication.

When to Seek Help

Immediate medical attention is required for any suspected overdose or if signs of severe toxicity are observed, including evidence of severe GI distress, hepatic impairment, or renal compromise.

Management, as described in regulatory documents, centers on supportive measures, as no specific antidote is known for Deferasirox. In such events, treatment must be discontinued immediately. Close monitoring of both renal function (creatinine) and hepatic function (liver enzymes) is mandatory.

The official labeling notes that special considerations apply to specific populations, including an increased risk of serious or fatal adverse reactions in elderly patients and an increased risk of severe GI hemorrhage in individuals with low platelet counts.

Therapeutic Uses of Exjade

Treating Chronic Iron Overload from Blood Transfusions

Exjade (Deferasirox) is a supportive therapeutic option applied across domains for managing chronic iron overload (hemosiderosis) that is commonly used in patients requiring repeated blood transfusions for chronic conditions like beta-thalassemia major, certain myelodysplastic syndromes (MDS), and sickle cell disease. Use of the medication is generally applicable to adult and pediatric patients who fit the clinical criteria in these transfusion-dependent contexts.

Controlling Iron Accumulation and Assisting Organ Risk Management

The medication plays a role in managing conditions presenting with systemic discomfort related to iron and is relevant in chronic situations where the iron burden creates noticeable physiological strain. Exjade assists in managing the measurable iron indices, which contributes to easing the overall symptom load by managing the potential for organ functional stress. This action may assist with reducing the likelihood of long-term damage that iron deposition can cause to organs, especially the heart and liver, and supports general well-being during the patient's long-term management of chronic iron overload.

Quick Fact: Relief for Chronic Iron Overload

Property	Description
Therapeutic Scope	Management of chronic iron accumulation (Hemosiderosis).
Applicable Conditions	Chronic anemias requiring frequent transfusions, including beta-thalassemia, certain MDS, and sickle cell disease.
Primary Benefit	Supports the patient during long-term management and assists with reducing the likelihood of iron-related organ damage.

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Eligibility Scope

Category	Regulatory Statement
Use Allowed (Age)	ge 2 years for Transfusional Iron Overload (TIO); ge 10 years for Non-Transfusion-Dependent Thalassaemia (NTDT).
Use Not Established (Age)	Children under 2 years of age.
Absolute Contraindications	Severe Renal Impairment (eGFR <40 mL/min/1.73 m^2). Severe Hepatic Impairment (Child-Pugh Class C). Platelet counts <50 imes 10^9/ L. Poor performance status or advanced malignancies. Known hypersensitivity to the drug.

Condition-Specific Restrictions

Official labeling requires dose reduction in patients with moderate hepatic impairment (Child-Pugh B). Use is permitted in older adults (ge 65 years) but requires close monitoring due to a higher frequency of decreased organ function. The drug is not recommended in patients with low iron burden (e.g., serum ferritin consistently <500 mu g/L).

Pregnancy and Lactation Status

Use during pregnancy is not recommended unless the potential benefit clearly justifies the potential risk to the fetus, based on animal study data. Women are advised not to breastfeed during Exjade treatment as it is unknown if the drug is excreted in human milk.

Connection to the overall eligibility profile: Regulatory documents establish who can use the medicine by defining absolute contraindications related to organ function and disease status, which formally exclude certain populations. Specific age minimums delineate the approved pediatric patient groups, and warnings regarding pregnancy and lactation advise against use in those physiological states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deferasirox's interaction profile, as outlined in regulatory labeling, is classified based on metabolic, physicochemical, and pharmacodynamic effects with co-administered substances.

Official Interaction Statements

Classification	Interacting Substance(s)	Regulatory Finding
Contraindicated	Aluminum-containing Antacids	Co-administration is prohibited due to the potential for physicochemical interference that significantly decreases deferasirox absorption.
Exposure Reduction	Potent UGT Inducers (e.g., Rifampicin, Phenytoin)	These agents decrease deferasirox systemic exposure ( AUC) by inducing its primary clearance pathway (glucuronidation).
Exposure Increase	CYP2 C8 Substrates (e.g., Repaglinide)	Deferasirox is a CYP2 C8 inhibitor and significantly increases the plasma exposure ( AUC) of co-administered substrates like Repaglinide.
Increased Risk	Ulcerogenic/Hemorrhagic Drugs (e.g., NSAIDs, Corticosteroids)	Co-administration formally increases the risk of serious gastrointestinal irritation, ulceration, or hemorrhage.
Exposure Reduction	Cholestyramine (Bile Acid Sequestrant)	Co-administration significantly decreases deferasirox systemic exposure ( AUC).

Additional Constraints

Metabolic Modification: Deferasirox is also documented as a modest inducer of CYP3 A4 and may reduce the exposure of co-administered CYP3 A4 substrates. Co-administration with theophylline, a CYP1 A2 substrate, should be avoided.

Timing Restriction: The oral dispersible tablets must be administered on an empty stomach at least 30 minutes before food, due to the effect of food on bioavailability, as stated in regulatory documents.

Population-Specific Caution: The increased risk of gastrointestinal hemorrhage with ulcerogenic drugs is a specific regulatory caution for elderly patients (65 years).

Mechanism of Action

Selective Chelation and Sequestration of Ferric Iron ( Fe^3+)

Deferasirox functions as a tridentate chelator that selectively binds to ferric iron ( Fe^3+), including Non-Transferrin-Bound Iron (NTBI). By forming a stable, electrically neutral complex in a 2:1 ratio (two drug molecules per iron atom), the molecule sequesters the iron. This molecular action prevents the iron from catalyzing the Fenton reaction and generating free radicals. The chemical inactivation of redox-active circulating iron results in a subsequent reduction in systemic oxidative stress.

Intracellular Iron Mobilization and Enhanced Biliary Excretion

Due to the drug's lipophilic nature, it penetrates cell membranes to mobilize accumulated tissue iron deposits from parenchymal cells, notably within the liver and heart. The resulting Fe^3+-drug complex is then secreted into the bile for elimination via the feces, establishing the major excretory pathway. This continuous physiological process creates a sustained negative systemic iron balance, leading to the net mobilization and excretion of deposited iron.

Dosage and Administration Information

The administration of Exjade (deferasirox) tablets for oral suspension must strictly follow the instructions for preparation and dosing schedule to ensure proper use, as established by clinical guidelines.

Administration and Preparation

Instruction Category	Official Guideline
Route of Administration	Oral (as a suspension)
Preparation Requirements	Tablets for suspension must be completely dispersed by stirring in a small amount of liquid; do not chew or swallow tablets whole.
Liquid Volume	Doses less than 1000 mg must be dispersed in about 100 mL of liquid, while doses 1000 mg or greater require about 200 mL of liquid.
Permitted Liquids	Water, orange juice, or apple juice.
Procedural Step	The entire suspension must be drunk immediately after preparation. Any residue remaining in the glass should be mixed with a small volume of liquid and swallowed.

Dosing and Timing

Instruction Category	Official Guideline
Dosing Schedule	Once daily, at approximately the same time each day.
Timing with Meals	Must be taken on an empty stomach, at least 30 minutes before food.
Initial Dose (Transfusion)	Recommended starting daily dose is 20 mg/ kg body weight.
Dose Adjustment	Dose may be adjusted every three to six months based on monthly serum ferritin level trends, in steps of 5 to 10 mg/ kg. The maximum dose is 40 mg/ kg per day.
Missed Dose Rule	If a dose is missed, it should be taken as soon as possible on an empty stomach. If it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular schedule continued. Do not double the dose.
Age-Group Rule	Approved for use in patients 2 years of age and older.

These guidelines define a structured, fixed daily administration protocol that relies on precise tablet preparation and ingestion timing relative to meals to standardize drug exposure.

Recent Clinical Evidence

Research evidence / Overview of studies for Exjade

Evidence for use in Chronic Iron Overload in Transfusion-Dependent Anemias

Research has explored how this treatment was used in patients with chronic iron overload resulting from repeated blood transfusions, which is a condition characterized by functional limitations. The studies examined populations that included individuals with conditions such as beta-thalassemia major and sickle cell disease. Key outcomes that were monitored included changes in liver iron concentration (LIC) and changes in blood levels of ferritin.

Studies reported measurements of LIC and ferritin levels, and findings generally describe patterns observed in the studies where measurements of iron levels decreased over the observed time intervals. Some research describes how the treatment was associated with patterns where measurements of cardiac iron levels were stable or decreased, as measured by MRI scans, in the heavily iron-overloaded individuals studied. Evidence in this area includes findings from controlled trials, where this treatment was studied for one to two years, as well as from observational studies that monitored patient experiences in daily medical practice.

What remains uncertain is the direct link between these decreases in iron markers and patient survival over the entire course of a lifetime, as long-term effects are not fully established for this treatment specifically. Follow-up durations were limited in many of the initial comparative trials, and while surrogate markers like LIC were evaluated in detail, comparative evidence is lacking for certain groups with other underlying anemias, such as myelodysplastic syndromes, where data for certain groups remain insufficient.

Evidence for use in Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes

This treatment was evaluated in patients with thalassemia syndromes who experience iron overload even without frequent blood transfusions. The primary research scenario included a randomized, placebo-controlled trial that focused on patients who had a high initial level of iron in the liver. The main outcomes related to systemic or functional imbalance that were measured included Liver Iron Concentration (LIC) and serum ferritin.

Research describes that treatment was associated with reductions in measured LIC and serum ferritin levels over the course of the studies. These findings describe patterns observed in the studies over time compared to the group that received placebo, where iron levels generally remained stable or increased. The evidence contributes to understanding symptom patterns in patients with a high baseline iron burden.

What is still uncertain about Exjade

Despite the research that was conducted, several key areas remain uncertain about the use of this treatment. Long-term effects are not fully established regarding overall patient survival and outcomes related to systemic or functional imbalance, such as heart failure. Comparative evidence is lacking for many direct head-to-head comparisons against all other iron-reducing treatments across different underlying diseases.

Furthermore, findings were mixed regarding the correlation between iron levels in the blood (serum ferritin) and the measurements of iron in the organs, highlighting that evidence quality varies across studies depending on the method used to measure iron. Sample sizes were modest in certain disease groups, meaning certainty remains low for less common anemias. Finally, research provides context but not individual predictions regarding how an individual may respond compared to the group patterns observed in clinical studies.

Frequently Asked Questions (FAQ)

Common questions about Exjade (FAQ)

Q: What is the difference between Exjade and other iron chelators?

Exjade’s active ingredient, deferasirox, is officially described as an orally active and highly selective agent for binding iron. The regulatory information highlights that it offers a non-invasive alternative to older iron chelators that historically required prolonged infusions to be administered.

Q: How quickly should I expect Exjade to start lowering my ferritin levels?

Official information indicates that the body’s response to Exjade is monitored over time, not day-by-day. Dose adjustments are typically made every three to six months based on the trends in monthly serum ferritin levels. This suggests that the iron-reducing effect is assessed over a period of months.

Q: Can Exjade cause kidney problems?

Yes, official safety information states that common side effects include an increase in blood creatinine, which is a marker of kidney function. More serious reactions, including acute kidney injury or renal failure, have also been reported. The medicine is formally contraindicated in patients with severe renal impairment (severe kidney problems).

Q: What kind of monitoring tests are done regularly when taking Exjade?

According to official guidelines, routine monitoring is conducted to follow the drug's effect and check for potential side effects. This typically includes monthly checks of serum ferritin (iron levels), serum creatinine (kidney function), and serum transaminases (liver function), as well as regular eye and hearing examinations.

Q: Can Exjade interact with common over-the-counter pain relievers like ibuprofen?

Official safety data indicates that taking Exjade with certain ulcerogenic or hemorrhagic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, is associated with an increased risk of serious side effects. These risks include gastrointestinal irritation, ulceration, or hemorrhage.

Q: Is Exjade taken for life, or is the treatment temporary?

The official product information specifies conditions for treatment interruption, which depend on the patient's iron status. For example, therapy should be considered for stopping if the serum ferritin level consistently drops below 500 mu g/L (or 300 mu g/L in non-transfusion-dependent thalassemia patients).

Q: How does Exjade affect liver function?

Studies and regulatory documents report that common adverse reactions include an increase in transaminases, which are liver enzymes. There have also been reports of serious adverse reactions, including hepatic failure. The medicine is formally contraindicated in patients with severe hepatic impairment (severe liver problems).

Q: Is Exjade used to treat iron overload caused by hereditary hemochromatosis?

The official approved uses are for chronic iron overload resulting from blood transfusions and for chronic iron overload in non-transfusion-dependent thalassemia syndromes. While hereditary hemochromatosis is a cause of iron overload, it is not listed as an approved indication in the core regulatory documents.

Q: Does Exjade cure iron overload, or just manage it?

Official documentation describes Exjade as a medication for the treatment and management of chronic iron overload. The drug is intended to reduce existing iron deposits and maintain a negative iron balance, which is a process of ongoing management rather than a single permanent cure.

Q: Is it normal to feel tired when first starting Exjade?

Fatigue or unusual weakness has been listed as an uncommon side effect in clinical studies. Fatigue that is persistent or severe may warrant an evaluation by a healthcare provider, as it can occasionally be a symptom of more serious, though rare, issues.

Q: Are eye exams necessary while taking Exjade?

Yes, official safety information states that both a baseline and periodic ophthalmic (eye) examinations are to be performed while taking this medicine. This is due to uncommon reports of serious vision-related side effects such as cataract and maculopathy.

Q: Do I need to change my diet while on Exjade?

No specific general diet change is required, but official guidelines stress that the dispersible tablets must be taken on an empty stomach, at least 30 minutes before food. High-fat meals should be avoided with certain tablet formulations because they can affect how the body absorbs the medicine.

Q: Why is it important to take Exjade with a specific amount of water or juice?

The official preparation instructions specify a precise volume of liquid (either 100 mL or 200 mL, depending on the total dose) to ensure the tablets are completely dispersed. This ensures the medicine is properly dispersed, which supports consumption of the entire prescribed amount in the correct suspension form.

Q: Does alcohol interact with Exjade?

Official safety data suggests that drinking alcohol while taking deferasirox can increase the risk of certain central nervous system side effects, such as dizziness or fainting. It may also potentially contribute to the risk of gastrointestinal irritation.

Q: What are the signs that Exjade is working effectively?

Official documents define effectiveness by objective measurements. The primary signs that the medicine is working are a decreasing trend in serum ferritin levels in the blood and, in some patients, a reduction in Liver Iron Concentration (LIC), which is typically measured by MRI.

Q: Do research studies support Exjade's use for non-transfusion-dependent thalassemia?

Yes, regulatory documents indicate that the medicine is approved for this use. Clinical studies in patients with non-transfusion-dependent thalassemia (NTDT) showed that treatment was associated with significant reductions in measured Liver Iron Concentration (LIC) and serum ferritin levels over the course of the studies.

Q: Is there a taste associated with the Exjade suspension?

Based on information related to its development, the original dispersible tablets (Exjade) are known to have a chalky consistency and specific taste. This led to the development of a newer film-coated tablet formulation that can be swallowed whole.

Q: What's the difference in the formulation between Exjade and the newer deferasirox products?

The original Exjade is a dispersible tablet that must be fully mixed in a liquid before consuming. Newer formulations, such as the film-coated tablet (often marketed under a different name), can be swallowed whole and have higher bioavailability, meaning a smaller milligram dose is needed for a comparable effect.

Q: How long after taking Exjade should I wait before eating certain foods?

According to official administration instructions for the dispersible tablets, the medicine must be taken on an empty stomach. This means you must wait at least 30 minutes after taking the dose before consuming any food.

Q: What is the purpose of the routine hearing checks while taking Exjade?

Official prescribing information requires baseline and periodic auditory (hearing) examinations because deafness and hearing loss have been reported as uncommon adverse reactions in some patients taking this medicine.

Q: Can Exjade cause digestive upset like diarrhea?

Yes, official safety data lists diarrhea, nausea, vomiting, and abdominal pain as common adverse reactions in patients taking Exjade. These effects are often observed at the beginning of treatment.

Q: Does Exjade interact with birth control pills?

Exjade is known to be a moderate inducer of CYP3A4, a major enzyme in the body. If hormonal birth control pills are metabolized by this enzyme, Exjade could potentially reduce their exposure, which may decrease their effectiveness. Patients using hormonal contraceptives should consult their healthcare provider about whether alternative or additional non-hormonal contraception methods are appropriate.

Q: What should I do if I get a rash after starting Exjade?

Skin rashes are listed as common and often become less frequent over time or resolve spontaneously. However, if a severe skin reaction, such as Stevens-Johnson syndrome, is suspected, official guidelines recommend immediate discontinuation of the medicine and seeking medical attention.

Q: Why is iron overload dangerous, and how does Exjade help?

Iron overload is dangerous because excess iron can deposit in and damage vital organs. Exjade helps by selectively chelating (binding to) the harmful ferric iron, which prevents the iron from reacting with other molecules in the body. The resulting iron-drug complex is then removed from the body primarily via the feces.

Q: Can people with certain allergies take Exjade?

Official documents list known hypersensitivity (a severe allergic reaction) to deferasirox or any of its ingredients as an absolute contraindication. If a patient has known allergies to the drug, its use is formally prohibited.

Q: Is Exjade considered a first-line treatment for chronic iron overload?

The regulatory documents indicate Exjade is approved for use in certain patient groups with chronic iron overload due to blood transfusions. It is also indicated for use when an alternative chelator is either inadequate or cannot be used, positioning it as a key therapeutic option.

Q: Is it normal for my iron levels to fluctuate slightly while on Exjade?

Official dosing guidelines focus on the trends in monthly serum ferritin levels over several months, rather than on a single reading. This suggests that some slight fluctuation in a monthly level may be observed, and treatment decisions are made based on the overall pattern.

Q: What are the signs of a serious allergic reaction to Exjade?

Official warnings state that a serious allergic reaction (hypersensitivity) may include signs such as difficulty breathing, swelling of the face, lips, tongue, or throat, or hives. These reactions are considered medical emergencies and require immediate medical attention.

Q: Does taking Exjade in the morning versus evening make a difference?

Official dosing guidelines specify that the medicine should be taken once daily, at approximately the same time each day. Whether this is in the morning or evening is not specified, as long as consistency is maintained and the empty-stomach rule is followed.

Q: Are there specific instructions for traveling with Exjade?

While there are no specific travel instructions, official storage guidelines state the medicine must be kept in its original, tightly closed container at controlled room temperature (between 20 C and 25 C) and protected from moisture.

Q: Can Exjade affect my ability to drive or operate machinery?

Official warnings note that side effects such as dizziness have been reported. It is important to exercise caution when engaging in activities that require focus, such as driving or operating heavy machinery, until the individual knows how the medicine affects them.

How should Exjade be stored and disposed of?

How to Store and Dispose of Exjade (Deferasirox)

The storage and disposal of Exjade tablets must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection	Keep the product in its original, tightly closed container and protect from moisture. Do not refrigerate or freeze.
Child Safety	The medicine must be kept out of the sight and reach of children.

Handling and Disposal

After Preparation: The oral suspension, once mixed with liquid, must be consumed immediately.
Disposal: Unused or expired Exjade should be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before discarding in the household trash. It must not be disposed of by flushing down a toilet or pouring into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.